GlassScriptPhysician profile
Charles A Joseph
NPI 1285675090
$2,115.53
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,205 · 2020: $249 · 2021: $649 · 2022: $12.03.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $240.76 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $221.81 | 2019-2021 | |
| Abbvie INC. | $215.32 | 2019-2022 | |
| Pfizer INC. | $165.81 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.36 | 2019-2021 | |
| Amgen INC. | $152.75 | 2019 | |
| Allergan, INC. | $150.59 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $150.00 | 2019-2020 | |
| Novo Nordisk INC | $127.39 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $72.78 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $70.35 | 2019-2021 | |
| Horizon Therapeutics Plc | $68.85 | 2019 | |
| Amarin Pharma, INC. | $64.33 | 2019-2021 | |
| Genentech USA, INC. | $40.99 | 2020-2021 | |
| Glaxosmithkline, LLC. | $39.44 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $26.31 | 2021 | |
| Hikma Pharmaceuticals USA | $25.83 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $23.15 | 2019 | |
| Arbor Pharmaceuticals, INC. | $22.72 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $14.32 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.14 | 2020 | |
| Novartis Pharmaceuticals Corporation | $14.03 | 2019 | |
| Sanofi Pasteur INC. | $14.00 | 2019 | |
| Eyevance Pharmaceuticals LLC | $12.17 | 2021 | |
| Astellas Pharma US INC | $11.33 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.